Ketamine Infusion Therapy
What is Ketamine Infusion Therapy?
Ketamine is a remarkably versatile substance. Originally used as an anesthetic, it is now a cutting-edge medication administered by infusion to combat a variety of psychiatric ailments. The drug has been in use since the 1960s as an anesthetic and has a track record of research substantiating its safety. Its therapeutic “off label” use in psychiatric patients began in 2017. For this reason, Ketamine, while FDA-approved as an anesthetic, is not yet FDA-approved for the treatment of psychiatric illness. The major problem this creates is that it keeps the treatment expensive since insurance companies do not yet cover it. Nonetheless, for the patients who have reaped its benefits, it is priceless. At APS Ketamine, we exclusively provide Ketamine infusions for patients suffering psychiatric symptoms.
What Conditions Ketamine Treats
Ketamine Infusion Therapy had been found to effective in treating:
- Severe depression
- Generalized anxiety
- Post Traumatic Stress Disorder (PTSD)
- Obsessive Compulsive Disorder (OCD)
- Panic disorders
- Alcohol and Cocaine Use Disorders
In more and more cases, Ketamine is the best option for patients not helped by antidepressants.
Your Best Choice for Ketamine Infusion Therapy in the Chicago Area
APS Ketamine is a facility focusing exclusively on providing Ketamine infusions in an atmosphere of comfort and calm. Ours was the second outpatient Ketamine clinic established in Illinois and the first one run by a psychiatrist: Abid Nazeer MD who is board-certified in Psychiatry/Neurology as well as in Addiction Medicine. Also, APS Ketamine became an early member of the American Society of Ketamine Physicians. We are the only clinic in the Chicago area to maintain membership in this national organization. Our office has administered over 500 infusions, all in the context of total mental healthcare. Dr. Nazeer is accompanied by a full-time advanced practice nurse and one full time registered nurse, all of whom provide careful monitoring of patients’ vital signs and mental status during and after treatment.
Now located in Oakbrook, Illinois, our practice is rapidly growing; We have opened the second branch of APS Ketamine in downtown Chicago to meet the increased demand for Ketamine Infusion Therapy. We have had patients who have travelled to us not only from Chicago and its suburbs, but from as far away as from Springfield, Illinois and Milwaukee, Wisconsin. As anyone who has suffered intractable psychiatric illness can attest, distance is a small obstacle to overcome when seeking relief. Because there are so few providers of Ketamine infusions in our area, and we are the only center supervised by a psychiatrist, patients are willing to travel many hours to receive the help they desperately need.
Proven Record of Safety
Because Ketamine has been in use for approximately 40 years with an outstanding record of safety, you needn’t be concerned about the safety of receiving Ketamine infusions. Currently, the medication is still used worldwide as an anesthetic, primarily in children. It has a distinct advantage over other anesthetic drugs since Ketamine does not slow down vital bodily functions such as respiration rate. Ketamine can increase blood pressure and heart rate for some patients, but this is a very temporary and transient effect. Ketamine, is considered much safer than traditional anesthetics.
Perhaps even more importantly, Ketamine, when administered by infusion for psychiatric reasons, is administered at much lower doses than when used as an anesthetic. Its side effect profile during the time it has been in psychiatric use is considerably better than that of oral antidepressant medications. All studies so far, performed during the past 10 years, have not shown negative outcomes. As a matter of fact, at APS Ketamine, Dr. Nazeer reports that he has “never had to stop an infusion due to adverse event or side effect even once.” Because long-term risks are still being studied, a bit more time must elapse before Ketamine receives FDA approval, but that approval is certainly expected.